OncoMatch/Clinical Trials/NCT05475925
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Is NCT05475925 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies DR-01 for lgll - large granular lymphocytic leukemia.
Treatment: DR-01 — This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Prior therapy
Lab requirements
Blood counts
sufficient key organ performance and coagulation
Kidney function
sufficient key organ performance
Liver function
sufficient key organ performance
Sufficient key organ performance and coagulation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dren Investigational Site · Birmingham, Alabama
- Dren Investigational Site · Duarte, California
- Dren Investigational Site · Irvine, California
- Dren Investigational Site · Redwood City, California
- Dren Investigational Site · New Haven, Connecticut
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05475925 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify